Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
Phase 3
Completed
- Conditions
- Urinary Incontinence Stress
- Registration Number
- NCT00191204
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 363
Inclusion Criteria
- Female out patients
- Are ambulatory and are able to use a toilet independently and without difficulty.
Exclusion Criteria
- Use of monoamine oxidase inhibitors (MAOIs)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method The primary objective of this study is to generate long-term safety data for duloxetine in the treatment of women with stress urinary incontinence.
- Secondary Outcome Measures
Name Time Method The secondary objective of this study is to collect data to demonstrate the maintenance of effect of duloxetine on patients quality of life, measured by Patient Impression of Improvement questionnaire.
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours EST), or speak with your personal physician.
🇬🇧Peterborough, United Kingdom
For additional information regarding investigative sites for this trial contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours EST), or speak with your personal physician.🇬🇧Peterborough, United Kingdom